相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes
J. Glaspy et al.
BRITISH JOURNAL OF CANCER (2010)
Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996)
Peter L. Greenberg et al.
BLOOD (2009)
Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus ≥ 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled
Johan Vansteenkiste et al.
BMC CANCER (2009)
Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis
Marcello Tonelli et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2009)
Initiation of Epoetin-α Therapy at a Starting Dose of 120,000 Units Once Every 3 Weeks in Patients With Cancer Receiving Chemotherapy An Open-Label, Multicenter Study With Randomized and Nonrandomized Treatment Arms
John A. Glaspy et al.
CANCER (2009)
An Assessment of Erythroid Response to Epoetin α as a Single Agent Versus in Combination With Granulocyte- or GranulocyteMacrophage-Colony-Stimulating Factor in Myelodysplastic Syndromes Using a Meta-Analysis Approach
Suneel Mundle et al.
CANCER (2009)
Role of recombinant human erythropoietin in patients of advanced cervical cancer treated by chemoradiotherapy
Seema Gupta et al.
CANCER BIOLOGY & THERAPY (2009)
Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia
Enrique Hernandez et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
What is the impact of antithrombotic therapy and risk factors on the frequency of thrombovascular events in patients with metastatic breast cancer receiving epoetin beta?
Matti Aapro et al.
EUROPEAN JOURNAL OF CANCER (2009)
Weekly Administration of Epoetin Beta for Chemotherapy-induced Anemia in Cancer Patients: Results of a Multicenter, Phase III, Randomized, Double-blind, Placebo-controlled Study
Masahiro Tsuboi et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2009)
Effect of Epoetin Alfa on Survival and Cancer Treatment-Related Anemia and Fatigue in Patients Receiving Radical Radiotherapy With Curative Intent for Head and Neck Cancer
Peter J. Hoskin et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
American Society of Clinical Oncology Guidance Statement: The Cost of Cancer Care
Neal J. Meropol et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Patterns of Use and Risks Associated With Erythropoiesis-Stimulating Agents Among Medicare Patients With Cancer
Dawn L. Hershman et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials
Julia Bohlius et al.
LANCET (2009)
A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
Marc A. Pfeffer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
The use of erythropoiesis-stimulating agents in patients with non-myeloid hematological malignancies: a systematic review
Nadine Shehata et al.
ANNALS OF HEMATOLOGY (2008)
Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis
Victor Moyo et al.
ANNALS OF HEMATOLOGY (2008)
Tumor Progression Associated with Erythropoiesis-Stimulating Agents
Ashley M. Newland et al.
ANNALS OF PHARMACOTHERAPY (2008)
Prevention of anaemia by early intervention with once weekly epoetin alfa during chemotherapy
J. H. Schoulwink et al.
EUROPEAN JOURNAL OF CANCER (2008)
Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer
Gillian Thomas et al.
GYNECOLOGIC ONCOLOGY (2008)
Erythropoiesis-Stimulating Agents in the Treatment of Cancer-Associated Anemia—Reply
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia
Charles L. Bennett et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Use of epoetin and darbepoetin in patients with cancer: 2007 American society of clinical oncology/American society of hematology clinical practice guideline update
J. Douglas Rizzo et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Darbepoetin alfa for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled study
Robert E. Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alfa administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia
Laurent Bastit et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alfa
Paolo Pedrazzoli et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia
James R. Wright et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A Randomized trial comparing immediate versus delayed treatment of anemia with once-weekly epoetin alfa in patients with non-small cell lung cancer scheduled to receive first-line chemotherapy
Jeffrey Crawford et al.
JOURNAL OF THORACIC ONCOLOGY (2007)
A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia
Veena Charu et al.
ONCOLOGIST (2007)
Efficacy and safety of erythropoiesis-stimulating proteins in myelodysplastic syndrome: A systematic review and meta-analysis
Susan D. Ross et al.
ONCOLOGIST (2007)
Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer
Charles L. Bennett et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Quality-of-life and health benefits of early treatment of mild anemia - A randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies
David J. Straus et al.
CANCER (2006)
Recombinant human erythropoietins and cancer patients: Updated meta-analysis of 57 studies including 9353 patients
Julia Bohlius et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Recombinant human erythropoietin in oncology: current status and further developments
A Engert
ANNALS OF ONCOLOGY (2005)
Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study
B Leyland-Jones et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes:: a randomized, controlled trial
N Casadevall et al.
BLOOD (2004)
Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy:: randomised, double-blind, placebo-controlled trial
M Henke et al.
LANCET (2003)
Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies:: a randomized, double-blind, placebo-controlled study
M Hedenus et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Use of epoetin in patients with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology
JD Rizzo et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Epoetin treatment of anemia associated with cancer therapy: A systematic review and meta-analysis of controlled clinical trials
J Seidenfeld et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2001)
分享论文
